Bio-Techne Corporation, a developer and manufacturer of life science reagents and instruments, announced it made an investment in Wilson Wolf Manufacturing. Wilson Wolf, which focuses on the development and manufacture of cell production technology for use in cell and gene therapy (CGT), achieved trailing 12-month EBITDA of $55 million, triggering Bio-Techne's initial 20% investment in the company for $257 million. The deal implies a 100% interest valuation of $1.285 billion, representing a multiple of approximately 23.4x EBITDA.
Diagnostic Tools EBITDA Multiples
The implied multiple was on the high end of the range compared to other diagnostics and life sciences tools companies, signaling BioTechne's confidence in Wilson Wolf's growth potential and expertise in high-demand areas like cell and gene therapy and antibody-drug conjugates.
About Scope Research
The Scope Research Healthcare M&A Valuation Database currently has financial details for 180 diagnostics and life sciences deals going back to 2010, 77 of which include reported EBITDA multiples. The diagnostics / life sciences database can be purchased individually, while our affordable annual subscriptions provide access to all of our healthcare M&A databases and segments, updated continuously.
Don't hesitate to reach out to Will Hamilton at will@scoperesearch.co with questions about your specific situation.